| INTRODUC TI ON
Bladder cancer comprises approximately 1-2% of all naturally occurring cancers in dogs, a similar rate to that found in human. 1, 2 While more than 90% of BC found in dogs consist of intermediate-to highgrade invasive urothelial carcinomas, [3] [4] [5] low-grade, superficial transitional cell carcinoma (TCC) is very rare. Diagnosis of dog BC is usually at the late stage, and is then often impossible to treat. 4, [6] [7] [8] Although several experimental models of BC exist, including carcinogen-induced mouse models and genetically engineered mice, they do not completely reflect the characteristics of invasive or metastatic human BC. 9 Interestingly, naturally occurring dog BC closely mimics human muscle-invasive BC in its cellular and molecular characteristics including histopathological characteristics, biological behavior, local cancer invasion, distant metastases, molecular features, response to chemotherapy, and prognosis, [10] [11] [12] [13] suggesting that dog BC could be a relevant model for muscle-invasive human BC. 10, 14 Therefore, identification of diagnostic markers and investigation of the mechanisms involved in dog BC might be beneficial not only for the veterinary clinic but also for human patients with muscle-invasive BC.
Three-dimensional (3D) culture (organoids), derived from selfrenewing stem cells, typically recapitulates in vivo architecture, functions, and genetic and molecular signatures of the parent tumors. This technique holds great promise for use in medical research into the development of new personalized therapy, especially for cancer. 15, 16 In a previous study, we established a culture method for dog prostate cancer (PC) organoids using urine samples from PC diseased dogs. 17 The organoids recapitulated the tumor microenvironment of dog PC tissues and showed tumorigenesis in vivo. Furthermore, this model could be used to investigate sensitivity of anticancer drugs.
Conversely, dog BC organoids had never been established. We therefore collected urine samples from BC-diseased dogs and cultured these samples using the previously described urine-derived organoid culture method. Here, for the 1st time, dog BC organoids were generated and demonstrated that BC organoids could be useful for analysis of tumorigenesis and to determine the sensitivity of anticancer drugs. We also identified novel diagnostic marker candidates (MMP28, CTSE, CNN3, TFPI2, COL17A1, and AGPAT4) by analyzing RNA-seq data from urine-derived BC organoids.
| MATERIAL S AND ME THODS

| Materials
To generate dog BC organoids, cells from urine samples were mixed with Matrigel (BD Bioscience) and cultured with stem cell-stimulated medium, as described previously. 17 Anticancer drugs used were as Japan. Email: fu7085@go.tuat.ac.jp
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K E Y W O R D S
| Cell culture
Dog two-dimensional (2D) urothelial carcinoma cell lines were purchased from COSMO BIO CO., Ltd, and cultured in Dulbecco's Modified Eagle's Medium containing 10% fetal bovine serum (FBS;
Thermo Fisher Scientific Inc.).
| Generation of urine sample-derived BC organoids
Between February 2017 and October 2018, 17 urine and blood samples were collected from dogs diagnosed with BC based on their clinical symptoms and cytological examinations ( Figure S1 ). 
| Passaging of BC organoids
| Collection of normal bladder tissue
| Hematoxylin and eosin staining of BC organoids
Hematoxylin and eosin (H&E) staining of BC organoids was performed as described previously. 17, 18 Bladder cancer organoids were fixed in 4% paraformaldehyde (PFA) at room temperature for 2-3 h, and then 
| Mouse xenograft assay
Mouse xenograft assay of BC organoids was performed as described previously. 17 
| Cell viability assay of BC organoids
Cell viability assay of organoids was performed as described previously. 17, 19 Taking into consideration the therapeutic dose in clinic and pharmacokinetics in dogs, 10, [20] [21] [22] [23] [24] [25] we determined the appropriate concentration to be used for each drug in the cell viability assay.
Briefly, 5 × 10 3 cells of each BC organoid were seeded into 10 μL
Matrigel in a 96-well culture plate and incubated for 24 h. Next, cells
were treated with anticancer drugs at variable concentrations for 3 d. Cell viability was examined using an alamar blue kit (Thermo Fisher Scientific Inc.). Fluorescence (emission wavelength; 585 nm) was read on a microplate reader (TECAN).
| RNA-sequencing analysis
Total RNA was extracted from normal bladder tissues from healthy dogs, BC organoid samples and 2D urothelial carcinoma cell lines Initial quality control of RNA-seq data (FASTQ) for each sample was performed using cutadapt (version 1.8.3) and cmpfastq_pe.pl software. Reads were mapped to the reference genome (CamFam 3.1) using the STAR (version 2.5.1b) software. PCA was performed
TA B L E 2 Primers for real-time quantitative PCR analysis
Primer Sequence
to display differences between samples. Fragments per kilobase of transcript per million mapped reads were normalized using the trimmed mean of M value method.
| Quantitative real-time polymerase chain reaction
Total RNA was extracted from normal bladder tissues, organoid samples, 2D urothelial carcinoma cell lines, and blood samples using the NucleoSpin kit (Takara Bio Inc) according to the manufacturer's instructions. First-strand cDNA was synthesized using a Q uantiTect Reverse Transcription Kit (Q IAGEN). Q uantitative realtime PCR was performed using a QuantiTect SYBR I Kit (QIAGEN) and a StepOnePlus Real-Time PCR System (Applied Biosystems).
The ΔΔCq method was used for quantification. Specific primers used for dog CK5, DSG3, GATA3, ERBB2, MMP28, CTSE, CNN3,   TFPI2, COL17A1, AGPAT4, GAPDH, CK15, TGM2, GJB2, IL1R2, COL5A2, CDH3, CHST4, and ADORA2B are listed in Table 2 .
| Immunohistochemical staining of organoids
Immunohistochemical staining of BC organoids was performed as described previously. 17 After deparaffinization, sections were treated with 1% peroxidase for 30 min, then blocked with 1.5% NGS/PBS for 30 min. Sections were then incubated with primary antibodies (CK5; 1:200) at 4°C overnight followed by incubation with 
| Western blotting
Western blotting was performed as described previously. 26 Protein lysates were obtained by homogenizing normal bladder tissues, organoid samples, and 2D urothelial carcinoma cell lines with Cell Lysis Reagent (Sigma-Aldrich) containing 1% protease inhibitor cocktail (Sigma-Aldrich). Loading proteins (10 μg) were separated by SDS-PAGE (7.5%) and transferred to a nitrocellulose membrane (Wako).
After blocking with 0.5% skimmed milk, the membranes were incubated with primary antibody (CK5; 1:500, VCP; 1:500) at 4°C overnight followed by incubation with the secondary antibody (1:10 000 dilution, 1 h) and ECL Prime (GE Healthcare). Results were obtained with FujiFilm LAS-3000 and quantified using ImageJ densitometry analysis software (National Institutes of Health).
| Statistical analysis
Data shown are means ± SEM. Statistical evaluations were performed using one-way analysis of variance (ANOVA) followed by Bonferroni's test. P-values ≤0.05 were considered to be statistically significant.
| RE SULTS
| Generation of dog BC organoids
Urine sample-derived dog PC organoids were generated by our group in a previous study. As most dogs with BC also exhibit invasion and metastasis, 1, 27 we hypothesized that urine cells from BC diseased dogs would be useful for organoid culture. Urine samples from BC diseased dogs were collected and used to generate urine-derived organoids ( Figure 1A ). Urine cells were cultured using the method reported previously. 17 Cells from the urine samples from each BC diseased dog gradually formed organoids ( Figure 1B ) and were continually propagated by serial passage. The efficacy in establishing continually propagated organoid lines from BC dogs was approximately 70% (12 lines from 17 attempted samples). We observed that urine-derived organoids from each sample had spheroidal structures ( Figure 1C) , and a similar histology to dog urothelial carcinomas reported previously 27 ( Figure 1D ). For the immunofluorescence assay, expression of an epithelial cell marker, E-cadherin, was observed in all organoids ( Figure 1E ). Expression of urothelial cell markers, CK 7 ( Figure 1F ), CK20 ( Figure 1G ), and UPK3A, ( Figure 1H ) was also Figure S2 ). Similarly to previously found for urine sample-derived dog PC organoids, we observed that a fibroblast cell marker, vimentin, ( Figure 1I ) and a myofibroblast marker, α-SMA, ( Figure 1J ) were expressed around the organoids.
Expression of a proliferation cell marker, Ki67, ( Figure 1K ) was also observed in the organoids. These results suggested that urine sample-derived organoids from BC diseased dogs could recapitulate the characteristics of dog BC tissues.
| Tumorigenesis induced by BC organoids
We next examined the ability of dog BC organoids to form tumors in vivo. Injection of the organoids into immunodeficient mice successfully generated tumors within 6 wk (Figure 2A ). Cell clusters resembling the structure of organoids were observed in the BC organoid injection-derived tumor tissues ( Figure 2B ). As the xeno- 
| Effects of anticancer drugs on BC organoids
To demonstrate the use of BC organoids as a preclinical model for checking the sensitivity of anticancer drugs, we performed a 96-well
Matrigel cell viability assay, as described previously. 18, 19 Treatment with a nonselective cyclooxygenase (COX) inhibitor, piroxicam, had no effect on the cell viability of each BC organoid ( Figure 3A ,B).
Treatment with a pyrimidine antimetabolite, gemcitabine, had no effect on the cell viability of organoids, expect for the 2nd BC organoid 
| Effects of combination treatment with anticancer drugs on BC organoids
In the veterinary clinic, multiple anticancer drug therapies are used to treat BC diseased dogs. [28] [29] [30] [31] [32] However, it is difficult to predict which combination therapies will be effective for each BC diseased dog. We therefore investigated the response to several patterns of co-treatment with anticancer drugs using BC organoids. In three out of four BC organoids (Ors 1, 2, and 3), co-treatment with gemcitabine and cisplatin significantly improved responses compared with cisplatin alone, while it had no additional effects on one organoid (Or 4) ( Figure 4A ). In two out of four BC organoids (Or 1 Figure 4B ). These results suggested that response to co-treatment with anticancer drugs is different in each BC organoid, and that cell viability testing using BC organoids might become a useful tool for measuring differences in the sensitivity of combination therapies.
| RNA-sequencing analysis of BC organoids
We next investigated the difference between gene expression profiles from normal bladder tissues, 2D BC cell lines, and BC organoid samples using RNA-seq analysis. Expression of each sample was clearly separated in a PCA plot ( Figure 5A ). Differential expression analysis showed that several genes were differentially regulated in BC organoid samples compared with normal bladder tissues or 2D BC cell lines ( Figure 5B ). In muscle-invasive human BC, a basal-like subtype showed a more aggressive phenotype than a luminal-like subtype. 33, 34 However, the main subtype of dog BC remains unclear. We therefore compared the expression levels of basal or luminal cell markers in BC organoids using a heat map Figure 5D ), while expression of GATA3 and ERBB2 mRNA was significantly downregulated compared with normal bladder tissues ( Figure 5E ). We further observed that CK5 protein was expressed in BC organoids as determined by immunohistochemistry ( Figure 5F ). Furthermore, we confirmed by western blotting that the expression of CK5 in BC organoids was significantly increased compared with 2D cells (Figure 5G, H) . These results indicated that the main type of dog BC might be a basal-like subtype, as is the case for human muscle-invasive BC.
| Searching for novel diagnostic makers using BC organoids
To explore novel diagnostic marker genes using dog BC organoids, we analyzed RNA-seq data and picked up the top 30 highly upregulated genes in dog BC organoids compared with normal bladder tissues (Table 3 ) or 2D BC cell lines (Table 4) . To validate the RNA-seq data, we prepared an additional three strains of normal bladder tis- Figure S3 ). We also confirmed that expression levels of these genes were quite low in the 2D BC cell lines and significantly lower compared with each BC organoid ( Figure 6A-F) .
Other selected genes (CK15, TGM2, GJB2, IL1R2, COL5A2, CDH3, CHST4, and ADORA2B) were not upregulated in some BC organoids or upregulated even in normal bladder tissues ( Figure S4 ). Finally, we observed that MMP28, CTSE, CNN3, TFPI2, and AGPAT4 proteins were expressed in BC organoids ( Figure 6G ).
| D ISCUSS I ON
In the current study, for the 1st time, dog BC organoids were generated and several genes specifically upregulated in the or- were specifically upregulated in the BC organoids ( Figure 6 ).
Collectively, our data suggest that dog BC organoids might become a new tool to provide new insights for both dog BC therapy and diagnostic markers.
Dog BC, also classified as TCC, is usually a high-grade invasive cancer. Treatments for dogs with BC, such as surgery, radiation therapy, medical therapy, and local intravesical therapy were conducted. As BC diseased dogs usually have severe conditions and it was difficult to perform surgery or tissue biopsy prior to treatment, in the present study we could not obtain tissue samples to compare histology between original tumor tissues and generated organoids, as shown in our previous dog PC organoid paper. 17 Furthermore, surgical resection in dogs with BC is limited due to the trigonal location (difficult for surgical operation) and metastases at the time of diagnosis. 35 Therefore, systemic medical therapies, including chemotherapy agents (cisplatin, vinblastine, and gemcitabine) and COX inhibitors (piroxicam), are considered to be mainstay treatments. 13, 35 In particular, oral piroxicam (0.3 mg/kg daily with food) is known to be a useful palliative treatment for dogs with BC, which provides excellent quality of life. 13 The direct effects of these drugs on patient-derived BC cells, however, have never been investigated. In the present study, for the 1st CK5  DSG3  TP63  CDH3  DSP  CD44  CK4  GATA3  ERBB2  FOXA1  FABP4  CK8  CK18  ERBB3 time, dog BC organoids were generated (Figures 1,2 ) and showed that piroxicam had no effect on cell viability of dog BC organoids ( Figure 3A,B) . In contrast, treatment with cisplatin or vinblastine decreased cell viability of BC organoids in a dose-dependent manner, similarly to the clinical use of cisplatin 28, 36 and vinblastine 37, 38 in the treatment of BC dogs. Interestingly, gemcitabine had no effect on most strains of dog BC organoids, except for the 2nd dog BC organoids (Figures2 and 3C) . To clarify the difference in gemcitabine sensitivity, the expression levels of genes involved in gemcitabine metabolism (dCK, CDA, RRM1, RRM2, and SLC29A1)
were measured using RNA-seq ( Figure S5 ). However, no correlation between the sensitivity and gene expression pattern in organoids was found. Further investigations using dog BC organoids are needed to measure drug sensitivity and to select a suitable medical therapy for each BC diseased dog.
In the treatment of dog BC, medical therapy is not usually curative, and resistance to one drug often develops. Once treatment is tolerated, dogs sequentially receive multiple different treatment protocols over the course of their disease. 13 The pattern of combination chemotherapy such as with cisplatin and piroxicam, 28, 29, 39 carboplatin and piroxicam, 40 vinblastine and piroxicam 41 has been reported.
For example, piroxicam enhanced the antitumor activity of carboplatin 40 and cisplatin 28, 29, 39 in dog BC. Piroxicam also significantly increased the activity of vinblastine in dog BC. 41 However, renal toxicity is especially problematic when cisplatin is combined with piroxicam. 28 In a previous report, the combination of cisplatin and piroxicam led to effective remission rates, but caused renal, gastrointestinal, and bone marrow toxicities. Considering these studies, simultaneous treatment with multiple chemotherapeutic agents might be more toxic than curative. It also remains unknown whether it would be more appropriate to simultaneously combine multiple chemotherapy agents in dogs with BC. To solve these problems, we measured which anticancer drug combination treatment affected cell viability of BC organoids. Co-treatment with gemcitabine and cisplatin or vinblastine was more effective than piroxicam (Figure 4) suggesting that, in the future, use of a cell viability assay for BC organoids would predict the most effective combination treatment for dogs. [48] [49] [50] [51] and mice, 42 suggesting that the origins of muscle-in- In the present study, we found that expression levels of MMP28, CTSE, CNN3, TFPI2, COL17A1, and AGPAT4 were specifically upregulated in dog BC organoids ( Figure 6 ). MMP28 is a member of metalloproteinase family; 52 it is expressed in many normal tissues and has a role in the production of cytokines and growth factors. 53, 54 CTSE is an aspartic endopeptidase belonging to the cathepsin family of proteases and functions mainly to liberate peptide epitopes for antigen presentation. 55, 56 CNN3 is involved in the regulation of cell migration 57, 58 65 In a previous study, expression levels of MMP28
were associated with human high-grade BC. 66 Overexpression of CTSE is associated with several types of cancer including human noninvasive BC. 67 These studies suggested that genes identified in the present study may be promising biomarkers for dog BC. Our established dog BC organoid system could become in the near future a useful tool to identify further novel biomarkers of both dog and human BC.
In conclusion, for the 1st time, we produced dog BC organoids from urine samples. The organoids showed tumorigenesis in vivo and basal-like subtype. It was also suggested that several genes might become biomarkers to predict the development of high-grade BC. Further studies on the dog BC organoid contribution to the treatment and diagnosis of both dog and human BC.
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